EA201691502A1 - Мутантные стафилококковые антигены - Google Patents
Мутантные стафилококковые антигеныInfo
- Publication number
- EA201691502A1 EA201691502A1 EA201691502A EA201691502A EA201691502A1 EA 201691502 A1 EA201691502 A1 EA 201691502A1 EA 201691502 A EA201691502 A EA 201691502A EA 201691502 A EA201691502 A EA 201691502A EA 201691502 A1 EA201691502 A1 EA 201691502A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- mutant
- staphylcoccic
- antigens
- mutant spa
- fhud2
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
- A61K2039/645—Dendrimers; Multiple antigen peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Предложен мутантный SpA со сниженной аффинностью к Fcγ-части человеческого IgG. Иммунизация с использованием EsxA, EsxB, FhuD2, Sta011, Hla и указанного мутантного SpA обеспечивает поразительные результаты в модели абсцесса почки, вызываемого инфекцией S.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14161861 | 2014-03-26 | ||
EP14192913 | 2014-11-12 | ||
PCT/EP2015/056175 WO2015144653A1 (en) | 2014-03-26 | 2015-03-24 | Mutant staphylococcal antigens |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201691502A1 true EA201691502A1 (ru) | 2017-04-28 |
EA037818B1 EA037818B1 (ru) | 2021-05-25 |
Family
ID=52706188
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201691502A EA037818B1 (ru) | 2014-03-26 | 2015-03-24 | Мутантные стафилококковые антигены |
Country Status (24)
Country | Link |
---|---|
US (1) | US10328140B2 (ru) |
EP (2) | EP3639850A1 (ru) |
JP (2) | JP6894237B2 (ru) |
KR (3) | KR102027429B1 (ru) |
CN (2) | CN112521464A (ru) |
AU (1) | AU2015238512B2 (ru) |
BE (2) | BE1022744B1 (ru) |
CA (1) | CA2942450A1 (ru) |
CY (1) | CY1122537T1 (ru) |
DK (1) | DK3122378T3 (ru) |
EA (1) | EA037818B1 (ru) |
ES (1) | ES2769647T3 (ru) |
HR (1) | HRP20200217T1 (ru) |
HU (1) | HUE047808T2 (ru) |
IL (2) | IL247328B (ru) |
LT (1) | LT3122378T (ru) |
MX (1) | MX2016012538A (ru) |
PL (1) | PL3122378T3 (ru) |
PT (1) | PT3122378T (ru) |
RS (1) | RS59971B1 (ru) |
SG (1) | SG11201606887WA (ru) |
SI (1) | SI3122378T1 (ru) |
WO (2) | WO2015144655A1 (ru) |
ZA (1) | ZA201605818B (ru) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2014002363A (es) * | 2011-09-01 | 2014-04-14 | Novartis Ag | Formulaciones de antigenos de staphylococcus aureus con adyuvante. |
EP4112638A1 (en) * | 2016-05-16 | 2023-01-04 | Access to Advanced Health Institute | Formulation containing tlr agonist and methods of use |
GB201802339D0 (en) | 2018-02-13 | 2018-03-28 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
CN109526985B (zh) * | 2018-11-19 | 2021-03-12 | 黑龙江省农垦科学院 | 土地类芽胞杆菌蛋白EsxA作为水稻稻瘟病生物防治剂的应用 |
EP3777884A1 (en) | 2019-08-15 | 2021-02-17 | GlaxoSmithKline Biologicals S.A. | Immunogenic composition |
KR20220107166A (ko) | 2019-10-02 | 2022-08-02 | 얀센 백신스 앤드 프리벤션 비.브이. | 스타필로코커스 펩티드 및 사용 방법 |
Family Cites Families (86)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE8205892D0 (sv) | 1982-10-18 | 1982-10-18 | Bror Morein | Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin |
EP0114787B1 (de) | 1983-01-25 | 1991-09-25 | Ciba-Geigy Ag | Neue Peptidderivate |
IL73534A (en) | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
US4680338A (en) | 1985-10-17 | 1987-07-14 | Immunomedics, Inc. | Bifunctional linker |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
US5238944A (en) | 1988-12-15 | 1993-08-24 | Riker Laboratories, Inc. | Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine |
US4929624A (en) | 1989-03-23 | 1990-05-29 | Minnesota Mining And Manufacturing Company | Olefinic 1H-imidazo(4,5-c)quinolin-4-amines |
CA2017507C (en) | 1989-05-25 | 1996-11-12 | Gary Van Nest | Adjuvant formulation comprising a submicron oil droplet emulsion |
US4988815A (en) | 1989-10-26 | 1991-01-29 | Riker Laboratories, Inc. | 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines |
US5389640A (en) | 1991-03-01 | 1995-02-14 | Minnesota Mining And Manufacturing Company | 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
SG70625A1 (en) | 1991-03-01 | 2000-02-22 | Minnesota Mining & Mfg | 1-Substituted 2-substituted 1H-imidazo(4, 5-c) quinolin-4-amines |
US5268376A (en) | 1991-09-04 | 1993-12-07 | Minnesota Mining And Manufacturing Company | 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
US5266575A (en) | 1991-11-06 | 1993-11-30 | Minnesota Mining And Manufacturing Company | 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines |
IL105325A (en) | 1992-04-16 | 1996-11-14 | Minnesota Mining & Mfg | Immunogen/vaccine adjuvant composition |
US5395937A (en) | 1993-01-29 | 1995-03-07 | Minnesota Mining And Manufacturing Company | Process for preparing quinoline amines |
HU219056B (hu) | 1993-03-23 | 2001-02-28 | Smithkline Beecham Biologicals Sa | 3-O-Dezacilezett monofoszforil-lipid A-t tartalmazó vakcinakészítmény |
AU681687B2 (en) | 1993-07-15 | 1997-09-04 | Minnesota Mining And Manufacturing Company | Imidazo(4,5-c)pyridin-4-amines |
US5352784A (en) | 1993-07-15 | 1994-10-04 | Minnesota Mining And Manufacturing Company | Fused cycloalkylimidazopyridines |
AU5543294A (en) | 1993-10-29 | 1995-05-22 | Pharmos Corp. | Submicron emulsions as vaccine adjuvants |
GB9326174D0 (en) | 1993-12-22 | 1994-02-23 | Biocine Sclavo | Mucosal adjuvant |
US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
US5482936A (en) | 1995-01-12 | 1996-01-09 | Minnesota Mining And Manufacturing Company | Imidazo[4,5-C]quinoline amines |
UA56132C2 (ru) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиция вакцины (варианты), способ стабилизации qs21 по отношению к гидролизу (варианты), способ приготовления вакцины |
DK1005368T3 (da) | 1997-03-10 | 2010-01-04 | Ottawa Hospital Res Inst | Anvendelse af nukleinsyrer, der indeholder ikke-metyleret CpG dinukleotid i kombination med alun som hjælpestoffer |
US6818222B1 (en) | 1997-03-21 | 2004-11-16 | Chiron Corporation | Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants |
JP5019494B2 (ja) * | 1997-04-01 | 2012-09-05 | コリクサ コーポレーション | モノホスホリルリピドaの水性免疫アジュバント組成物 |
US6080725A (en) | 1997-05-20 | 2000-06-27 | Galenica Pharmaceuticals, Inc. | Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof |
US6562798B1 (en) | 1998-06-05 | 2003-05-13 | Dynavax Technologies Corp. | Immunostimulatory oligonucleotides with modified bases and methods of use thereof |
US6110929A (en) | 1998-07-28 | 2000-08-29 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
GB9817052D0 (en) | 1998-08-05 | 1998-09-30 | Smithkline Beecham Biolog | Vaccine |
DE69935606T9 (de) | 1998-10-16 | 2021-03-11 | Glaxosmithkline Biologicals S.A. | Adjuvanzsysteme und impfstoffe |
US6776357B1 (en) | 1998-10-22 | 2004-08-17 | Yosuke Naito | Showerhead |
US20030130212A1 (en) | 1999-01-14 | 2003-07-10 | Rossignol Daniel P. | Administration of an anti-endotoxin drug by intravenous infusion |
US6551600B2 (en) | 1999-02-01 | 2003-04-22 | Eisai Co., Ltd. | Immunological adjuvant compounds compositions and methods of use thereof |
CA2361421A1 (en) | 1999-02-03 | 2000-08-10 | Biosante Pharmaceuticals, Inc. | Therapeutic calcium phosphate particles and methods of manufacture and use |
US6331539B1 (en) | 1999-06-10 | 2001-12-18 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
ES2298269T3 (es) | 2000-09-26 | 2008-05-16 | Idera Pharmaceuticals, Inc. | Modulacion de la actividad inmunoestimulante de analogos oligonucleotidicos inmunoestimulantes mediante cambios quimicos posicionales. |
US6660735B2 (en) | 2000-12-08 | 2003-12-09 | 3M Innovative Properties Company | Urea substituted imidazoquinoline ethers |
US6677347B2 (en) | 2000-12-08 | 2004-01-13 | 3M Innovative Properties Company | Sulfonamido ether substituted imidazoquinolines |
US6660747B2 (en) | 2000-12-08 | 2003-12-09 | 3M Innovative Properties Company | Amido ether substituted imidazoquinolines |
US6664260B2 (en) | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Heterocyclic ether substituted imidazoquinolines |
US6664265B2 (en) | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Amido ether substituted imidazoquinolines |
US6664264B2 (en) | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Thioether substituted imidazoquinolines |
UA74852C2 (en) | 2000-12-08 | 2006-02-15 | 3M Innovative Properties Co | Urea-substituted imidazoquinoline ethers |
US6667312B2 (en) | 2000-12-08 | 2003-12-23 | 3M Innovative Properties Company | Thioether substituted imidazoquinolines |
US6677348B2 (en) | 2000-12-08 | 2004-01-13 | 3M Innovative Properties Company | Aryl ether substituted imidazoquinolines |
WO2003035836A2 (en) | 2001-10-24 | 2003-05-01 | Hybridon Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends |
US6677349B1 (en) | 2001-12-21 | 2004-01-13 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
EP1511746A2 (en) | 2002-05-29 | 2005-03-09 | 3M Innovative Properties Company | Process for imidazo[4,5-c]pyridin-4-amines |
KR20070008625A (ko) | 2004-04-05 | 2007-01-17 | 화이자 프로덕츠 인코포레이티드 | 미세유체화된 수중유 유화액 및 백신 조성물 |
EP2298341A3 (en) * | 2004-10-21 | 2011-07-13 | Wyeth LLC | Immunogenic compositions of staphylococcus epidermidis polypeptide and polynucleotide antigens |
US20060228369A1 (en) | 2005-04-11 | 2006-10-12 | Program For Appropriate Technology In Health | Stabilization and preservation of temperature-sensitive vaccines |
US7691368B2 (en) | 2005-04-15 | 2010-04-06 | Merial Limited | Vaccine formulations |
US8703095B2 (en) | 2005-07-07 | 2014-04-22 | Sanofi Pasteur S.A. | Immuno-adjuvant emulsion |
TWI382019B (zh) | 2005-08-19 | 2013-01-11 | Array Biopharma Inc | 作為類鐸受體(toll-like receptor)調節劑之胺基二氮雜呯 |
GB0526038D0 (en) | 2005-12-21 | 2006-02-01 | Glaxosmithkline Biolog Sa | Immunogenic composition |
FR2896162B1 (fr) | 2006-01-13 | 2008-02-15 | Sanofi Pasteur Sa | Emulsion huile dans eau thermoreversible |
NZ574057A (en) | 2006-06-12 | 2012-01-12 | Glaxosmithkline Biolog Sa | Staphylococcal antigen composition comprising an isolated S. aureus type 5 antigen; an isolated S. aureus type 8 antigen; an isolated S. aureus 336 antigen; an isolated S. aureus alpha-toxin antigen; and an isolated Staphylococcal leukocidin antigen |
US8338593B2 (en) | 2006-07-07 | 2012-12-25 | Gilead Sciences, Inc. | Modulators of toll-like receptor 7 |
CN101522218B (zh) | 2006-10-12 | 2012-09-26 | 葛兰素史密丝克莱恩生物有限公司 | 包含水包油乳液佐剂的疫苗 |
US20090007256A1 (en) | 2007-06-28 | 2009-01-01 | Microsoft Corporation | Using a trusted entity to drive security decisions |
CA2697538C (en) | 2007-08-31 | 2019-02-12 | University Of Chicago | Methods and compositions related to immunizing against staphylococcal lung diseases and conditions |
PE20091236A1 (es) | 2007-11-22 | 2009-09-16 | Astrazeneca Ab | Derivados de pirimidina como immunomoduladores de tlr7 |
US8466167B2 (en) | 2008-03-03 | 2013-06-18 | Irm Llc | Compounds and compositions as TLR activity modulators |
PL2276486T3 (pl) | 2008-03-24 | 2014-04-30 | 4Sc Discovery Gmbh | Nowe podstawione imidazochinoliny |
DK2313111T3 (da) | 2008-08-01 | 2013-12-02 | Ventirx Pharmaceuticals Inc | Toll-lignende receptoragonistformuleringer og anvendelse deraf |
EP2208787A1 (en) * | 2009-01-19 | 2010-07-21 | Université de Liège | A recombinant alpha-hemolysin polypeptide of Staphylococcus aureus, having a deletion in the stem domain and heterologous sequences inserted |
KR20170102039A (ko) * | 2009-04-03 | 2017-09-06 | 유니버시티 오브 시카고 | 단백질 A(SpA) 변이체와 관련된 조성물 및 방법 |
PL2510947T3 (pl) * | 2009-04-14 | 2016-09-30 | Kompozycje do immunizacji przeciwko Staphylococcus aureus | |
AU2010290896B2 (en) | 2009-09-02 | 2014-07-03 | Glaxosmithkline Biologicals S.A. | Immunogenic compositions including TLR activity modulators |
US8808699B2 (en) * | 2010-04-05 | 2014-08-19 | The University Of Chicago | Compositions and methods related to protein A (SpA) antibodies as an enhancer of immune response |
CN103313725B (zh) | 2010-09-01 | 2016-06-29 | 诺华有限公司 | 免疫增强剂吸附不溶性金属离子 |
WO2012034067A1 (en) * | 2010-09-09 | 2012-03-15 | The University Of Chicago | Methods and compositions involving protective staphylococcal antigens |
MX2014002363A (es) | 2011-09-01 | 2014-04-14 | Novartis Ag | Formulaciones de antigenos de staphylococcus aureus con adyuvante. |
CN104023744A (zh) | 2011-12-23 | 2014-09-03 | 诺华股份有限公司 | 用于针对金黄色葡萄球菌免疫的稳定组合物 |
ES2597755T3 (es) | 2012-03-07 | 2017-01-20 | Glaxosmithkline Biologicals Sa | Sales de arginina de un agonista de TLR7 |
RU2014140521A (ru) | 2012-03-08 | 2016-04-27 | Новартис Аг | Адъювантные составы бустерных вакцин |
US9926344B2 (en) | 2012-08-31 | 2018-03-27 | Glaxosmithkline Biologicals Sa | Stabilised proteins for immunising against Staphylococcus aureus |
JP2015528456A (ja) | 2012-08-31 | 2015-09-28 | ノバルティス アーゲー | Staphylococcusaureusに対する免疫化のための安定化されたタンパク質 |
EP2890388A1 (en) * | 2012-08-31 | 2015-07-08 | Novartis AG | Stabilised proteins for immunising against staphylococcus aureus |
US20150202277A1 (en) | 2012-08-31 | 2015-07-23 | Novartis Ag | Stabilised proteins for immunising against staphylococcus aureus |
CN103694322B (zh) * | 2013-12-09 | 2016-08-17 | 成都欧林生物科技股份有限公司 | 金黄色葡萄球菌SpA5突变体及其制备方法和应用 |
CN103645318B (zh) * | 2013-12-09 | 2016-11-02 | 成都欧林生物科技股份有限公司 | 金黄色葡萄球菌SpA5突变体抗原特异性IgG抗体检测方法和检测试剂盒 |
-
2015
- 2015-03-24 LT LTEP15711523.9T patent/LT3122378T/lt unknown
- 2015-03-24 BE BE2015/5176A patent/BE1022744B1/fr not_active IP Right Cessation
- 2015-03-24 MX MX2016012538A patent/MX2016012538A/es active IP Right Grant
- 2015-03-24 ES ES15711523T patent/ES2769647T3/es active Active
- 2015-03-24 CN CN202011253615.7A patent/CN112521464A/zh active Pending
- 2015-03-24 JP JP2016558699A patent/JP6894237B2/ja active Active
- 2015-03-24 RS RS20200215A patent/RS59971B1/sr unknown
- 2015-03-24 HU HUE15711523A patent/HUE047808T2/hu unknown
- 2015-03-24 US US15/127,537 patent/US10328140B2/en active Active
- 2015-03-24 WO PCT/EP2015/056179 patent/WO2015144655A1/en active Application Filing
- 2015-03-24 EP EP19211691.1A patent/EP3639850A1/en not_active Withdrawn
- 2015-03-24 WO PCT/EP2015/056175 patent/WO2015144653A1/en active Application Filing
- 2015-03-24 CA CA2942450A patent/CA2942450A1/en active Pending
- 2015-03-24 PL PL15711523T patent/PL3122378T3/pl unknown
- 2015-03-24 SI SI201531080T patent/SI3122378T1/sl unknown
- 2015-03-24 KR KR1020197010177A patent/KR102027429B1/ko active IP Right Grant
- 2015-03-24 EA EA201691502A patent/EA037818B1/ru unknown
- 2015-03-24 BE BE20155175A patent/BE1022857A1/fr not_active IP Right Cessation
- 2015-03-24 AU AU2015238512A patent/AU2015238512B2/en active Active
- 2015-03-24 KR KR1020167028541A patent/KR20160132109A/ko active Application Filing
- 2015-03-24 DK DK15711523.9T patent/DK3122378T3/da active
- 2015-03-24 SG SG11201606887WA patent/SG11201606887WA/en unknown
- 2015-03-24 EP EP15711523.9A patent/EP3122378B1/en active Active
- 2015-03-24 CN CN201580014701.3A patent/CN106103469B/zh active Active
- 2015-03-24 KR KR1020197027986A patent/KR102297357B1/ko active IP Right Grant
- 2015-03-24 PT PT157115239T patent/PT3122378T/pt unknown
-
2016
- 2016-08-17 IL IL247328A patent/IL247328B/en active IP Right Grant
- 2016-08-22 ZA ZA2016/05818A patent/ZA201605818B/en unknown
-
2020
- 2020-01-30 CY CY20201100078T patent/CY1122537T1/el unknown
- 2020-02-11 HR HRP20200217TT patent/HRP20200217T1/hr unknown
- 2020-10-15 JP JP2020173955A patent/JP2021035950A/ja active Pending
-
2021
- 2021-04-06 IL IL282104A patent/IL282104A/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201691502A1 (ru) | Мутантные стафилококковые антигены | |
CY1122804T1 (el) | Μονοκλωνικα αντισωματα εναντι ανθρωπινου αντιγονου ωριμανσης β κυτταρων (βcμα) | |
EA201790569A1 (ru) | Антитела и иммуноконъюгаты против cll-1 | |
PH12016502518A1 (en) | Monoclonal antibodies against her2 epitope and methods of use thereof | |
EA201790545A1 (ru) | Антитела и иммуноконъюгаты против her2 | |
MA40682B1 (fr) | Anticorps anti-ox40 et procédés d'utilisation correspondants | |
EA201790984A1 (ru) | Анти-cd79b антитела и способы их применения | |
MX2019009660A (es) | Uso de anticuerpos antigeno 4 del linfocito t (ctla-4) con citotoxicidad celular dependiente de anticuerpos (adcc) mejorada para mejorar la respuesta inmune a una vacuna. | |
EA201791029A1 (ru) | Антитела против интерлейкина-33 и их применение | |
CL2018000728A1 (es) | Anticuerpos anti-cd19 humano humanizados y métodos de utilización | |
PH12016501435A1 (en) | Anti-jagged1 antibodies and methods of use | |
EA201600473A1 (ru) | ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К Tau(PS422) И СПОСОБЫ ПРИМЕНЕНИЯ | |
PH12016501366A1 (en) | Novel anti-baff antibodies | |
NZ710744A (en) | Methods for increasing immunoglobulin a levels | |
BR112017015880A2 (pt) | anticorpos, usos e métodos | |
EA201890747A1 (ru) | Способы лечения воспалительных заболеваний | |
EA201692554A1 (ru) | Менингококковые вакцины | |
BR112018002382A8 (pt) | Novos anticorpos anti-gvpi humano e usos dos mesmos | |
MX357061B (es) | Diseño de inmunogenos a base de linaje de celulas b con animales humanizados. | |
MX2019008779A (es) | Antigenos de pseudomonas y combinaciones de antigenos. | |
HK1243439A1 (zh) | Pcsk9抗體、其抗原結合片段及其醫藥用途 | |
MA39355A1 (fr) | Anticorps anti-ox40 et procédés d'utilisation correspondants | |
EP3231441A4 (en) | Novel protein structure produced by effective antibody used for immunization | |
NZ629420A (en) | Sheep nematode vaccine | |
EA201992003A1 (ru) | Применение антител к ctla-4 с повышенной adcc для усиления иммунного ответа на вакцину |